Formulations That Meet Unmet Patient Needs
Focused on long acting
Developing Finished Dosage Forms and a Portfolio of APIs
Fully integrated GMP
Pipeline of Multiple Late Stage Products
In Phase III for RMS and Phase II for
PPMS for treating MS
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Our main focus is on developing long acting depot injectable drugs.
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel – Dec. 21, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company,...
Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries
Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved NESS ZIONA, Israel – Oct. 7, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage...